Final clinical data of a phase 1 dose-escalation study ofWVT078, a BCMA£CD3 bispecific antibody, alone and incombination with γ-secretase inhibitor WHG626 in patientswith relapsed and/or refractory multiple myeloma
Schjesvold F, et al.
Cancer
April 2026
Authors and Affiliates
Fredrik Schjesvold MD, PhD1,2 | Andrew Spencer MBBS, FRACP, FRCPA, DM3 |Yael C. Cohen MD4,5 | Enrique M. Ocio MD, PhD6 | Jordi Lopez-Pardo MD7 |Anna Maria Cafro MD8 | Natalie S. Callander MD9 | Jonathan L. Kaufman MD10 |Meera Mohan MD, MS11 | Martin Wermke MD12 | Noriko Doki PhD, MD13 |Rebecca Kan MPH14 | Pedro Milanez-Almeida PhD14 | Andrew Stein PhD14 |Gina Trabucco MSc14 | Stan Ye PhD14 | Karolina Kulec MSc15 |Romain Sechaud PhD16 | Souvik Banerjee PhD17 | Huiqin Zhong PhD18 |Clinton Lai MBChB, FFPM18 | Philipp J. Rauch MD16 | Marc S. Raab MD191Oslo Myeloma Center, Department of Hematology, OSLO University Hospital, Oslo, Norway2KG Jebsen Center for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway3The Alfred Hospital, Monash University, Melbourne, Victoria, Australia4Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel5Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel6Hospital Universitario Marqués de Valdecilla, Idival, Santander, Spain7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain8Department of Hematology, GOM Niguarda Hospital, Milan, Italy9Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA10Winship Cancer Institute, Emory University, Atlanta, Georgia, USA11Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA12NCT/UCC Early Clinical Trial Unit, Universitatsklinikum Carl Gustav Carus an der Technische Universitat, Dresden, Germany13Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan14Novartis Biomedical Research, Cambridge, Massachusetts, USA15Novartis Ireland Limited, Dublin, Ireland16Novartis Biomedical Research, Basel, Switzerland17Novartis Healthcare Pvt, Ltd, Hyderabad, India18Novartis Institutes for BioMedical Research, Shanghai, China19Heidelberg Myeloma Center Department of Medicine V, Medical Faculty and University Hospital, Heidelberg, Germany